Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ziconotide (Elan Pharmaceuticals).

C E Heading1

  • 1moore11@globalnet.co.uk

Idrugs : the Investigational Drugs Journal
|July 19, 2005
PubMed
Summary
This summary is machine-generated.

Ziconotide, a novel N-type calcium channel blocker, demonstrated significant pain reduction in patients with intractable pain. This drug was safe and well-tolerated in clinical trials for severe pain management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AD-5423 Dainippon Pharmaceutical Co Ltd.

IDrugs : the investigational drugs journal·2008
Same author

Common ground in therapy of substance abuse.

IDrugs : the investigational drugs journal·2005
Same author

Glycine absorption from the small intestines of rats after secondary infections with Eimeria nieschulzi.

Experientia·1986
Same author

Intestinal absorption studies with glycyl-proline, glycine and ethanol in rats infected with Eimeria nieschulzi.

Life sciences·1985
Same author

Glycylproline absorption in rats infected with Eimeria nieschulzi.

Biochemical Society transactions·1981
Same author

Absorption of glycine and proline from the small intestine of rats infected with Eimeria nieschulzi.

Experientia·1980
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Neurology

Background:

  • Elan Pharmaceuticals is developing ziconotide, a neuron-specific N-type calcium channel blocker.
  • Ziconotide is being investigated for the treatment of severe pain and ischemia.

Purpose of the Study:

  • To evaluate the efficacy and safety of ziconotide in patients with intractable pain.
  • To assess the potential of ziconotide in treating ischemia associated with head trauma and stroke.

Main Methods:

  • Pivotal studies involved over 700 patients receiving intrathecal ziconotide for intractable pain.
  • Phase III trials for ischemia are ongoing.
  • Development of orally available nonpeptide analogs is also underway.

Main Results:

  • Ziconotide showed a significant reduction in pain compared to placebo in pivotal studies.

Related Experiment Videos

  • The drug was safe and well-tolerated in patients, including those who failed morphine therapy.
  • Treatment was effective over periods as long as 3 years.

    • Conclusions:

    • Ziconotide is a promising treatment for intractable pain, offering significant relief and a favorable safety profile.
    • Further research is ongoing for its application in ischemia-related conditions.